AstraZeneca Takes Full Ownership of Omniose in Biotech Acquisition

AstraZeneca acquired Omniose, a St. Louis-based biotech developing vaccines for bacterial infections. The deal follows a three-year research collaboration. Omniose's pipeline targets Group B Streptococcus, Streptococcus pneumoniae, and Klebsiella pneumoniae. Financial terms were not disclosed. Omniose's 25 employees will join AstraZeneca's Infectious Disease Unit.

Amgen's tarlatamab combined with AstraZeneca's durvalumab extended median overall survival to 21.1 months in ES-SCLC patients, vs 12-13 months with standard therapy, per phase 3 trial results. The study showed a 58% reduction in death risk. Both companies plan regulatory filings.

London's FTSE 100 index rose 0.34% to 10,872.62 points by 11:31 GMT, driven by strong corporate earnings. Rolls-Royce gained 2.8% after announcing a £1.5B share buyback. AstraZeneca and GSK each rose around 1%. Burberry surged 9.4% on better-than-expected Q2 results.

AstraZeneca is acquiring Omniose, a bacterial vaccine biotech, for an undisclosed sum. Omniose's bioconjugation platform, which simplifies vaccine production, will be integrated into AstraZeneca's infectious disease unit. The acquisition follows a three-year research collaboration focused on vaccines for multidrug-resistant bacteria. AstraZeneca sees Omniose's technology as a differentiated approach to developing vaccines for serious bacterial infections.

AstraZeneca acquired Omniose, a St. Louis-based preclinical vaccine startup, for its technology that simplifies conjugate vaccine production. Omniose's platform produces the polysaccharide antigen, carrier protein, and linking enzyme in one E. coli cell, potentially reducing costs and variability. The acquisition follows a January 2024 research collaboration, with Omniose becoming a subsidiary of AstraZeneca's infectious disease unit. Financial terms were not disclosed.

AstraZeneca acquired Omniose, gaining bioconjugation tech for bacterial vaccine development. The FDA warned of a potential risk of vision loss with GLP-1 therapies. Compass Pathways submitted a U.S. approval application for its psilocybin-based depression treatment, COMP360.